Shilpa Medicare has received CDSCO approval for its successful innovation of first in world topical hemostatic spray of Tranexamic Acid. This novel formulation of spray is simple, easy to carry, convenient to use and a lifesaving tool. Clinically proven in humans and validated in robust swine trauma model. The product is approved for the usage of reducing or preventing hemorrhage and to reduce the need of replacement therapy during accidental and domestic injury.
The product is protected by granted patents in India till 2037 and in US, Australia, Russia and South Africa till 2038. Shilpa is continuously pursuing patent prosecution in other countries and for further protection.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
